Cardiotoxicity assays
Cardiac toxicity is responsible for a large percentage of new drugs that fail in clinical trials. The development of highly predictive in vitro assays suitable for highthroughput screening is critical to improve the ineffeciencies and high costs associated with cardiac safety compound failure.